Loading
A phase 1/2 trial of Vebreltinib in non-small-cell lung cancer and small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI is a phase 1/2 interventional study registered as NCT06343064 by Avistone Biotechnology Co., Ltd., with 156 participants planned, started 2023-06-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: Vebreltinib, PLB1004. Conditions listed: Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Avistone Biotechnology, Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer.
Shares Avistone Biotechnology, Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Avistone Biotechnology, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Avistone Biotechnology, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Vebreltinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.